about
Lighting the fires within: the cell biology of autoinflammatory diseasesRIP2 activity in inflammatory disease and implications for novel therapeuticsIdentification of benzimidazole diamides as selective inhibitors of the nucleotide-binding oligomerization domain 2 (NOD2) signaling pathwayWorking the endless puzzle of hereditary autoinflammatory disorders.Blau syndrome, the prototypic auto-inflammatory granulomatous diseaseIL-1 blockade in autoinflammatory syndromes.Aberrant interleukin-1 signalling does not increase susceptibility of mice to NOD2-dependent uveitis.Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes.Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice.The role of the innate immune system in granulomatous disorders.Monogenic autoinflammatory diseases: concept and clinical manifestations.Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issuesMonogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.Blau syndrome-associated uveitis and the NOD2 gene.Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature.The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.Genetically defined autoinflammatory diseases.A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner.Granulomas in the gastrointestinal tract: deciphering the Pandora's box.[Autoinflammatory syndromes in childhood].Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis.A novel nucleotide oligomerisation domain 2 mutation in a family with Blau syndrome: Phenotype and function.Casting the critical regions in nucleotide binding oligomerization domain 2 protein: a signature mediated structural dynamics approach.Blau syndrome and latent tubercular infection: an unresolved partnership
P2860
Q26827163-B6C665FA-F425-421B-B922-4C3770C7BA47Q27025050-CC67C548-EE07-4D4F-9885-9EA5953B1129Q28535051-1F08875B-04DC-4C39-B3AA-08FB92DA79DDQ33357128-44BF5CF6-ACC9-4AA7-923D-5F0498E737B1Q34060987-9636F957-7B02-4088-9685-6C571ADCB482Q34262561-8E502B3C-431B-4F47-904B-F4848FEA86D9Q35220614-AE31D02A-A77B-4891-9E2C-18AF7D256C3DQ35443835-3B658D99-D70C-4C63-BE67-52113BDABA0EQ36041225-18BB67CA-B89D-425A-ABCB-1E484B07F9BBQ36490486-2F3C8127-272E-44BC-AD6E-60656012933CQ36872083-711C541C-CDA9-4432-B995-7C57260F2501Q37162157-AAE0CF22-8553-41E1-9153-AE758BD40680Q37299354-25662469-399E-4BF4-BD33-2038CEC324A9Q37466515-DDD655B5-0ACC-4957-8D9E-419D4562EE05Q38134785-B8B95D6B-EE7F-4C0B-810A-DA6240C990D3Q38180294-CD7B9611-9152-4589-900B-D971ED9D43DEQ38222307-FE5417EC-0D76-469C-A2D3-F1159E57E41BQ38720044-4DACB1CC-90EE-44A3-9771-B2306396ADA7Q38773387-35EC7AE2-4D67-4565-AFEE-B01420E59111Q40107019-E031F58E-EB43-45E9-A90A-006D7EEB0071Q40144768-151A44C5-7601-4860-93ED-A03C6A050EE3Q42075063-E2D17225-E5F6-4BE1-9997-4BDF976490CFQ47911970-F29FEC5D-D7AB-476C-BDD2-5E8B74EC6EA2Q48952209-A5328A1D-D153-4077-9F3B-7412D4DF480AQ58326086-F0BB731E-9C1E-491D-A4C4-18136121AC7F
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Blau syndrome revisited.
@en
Blau syndrome revisited.
@nl
type
label
Blau syndrome revisited.
@en
Blau syndrome revisited.
@nl
prefLabel
Blau syndrome revisited.
@en
Blau syndrome revisited.
@nl
P1476
Blau syndrome revisited
@en
P2093
Carlos D Rose
P304
P356
10.1097/BOR.0B013E328349C430
P577
2011-09-01T00:00:00Z